---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041422"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:22:26.824182+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Processa Pharma shareholders approve reverse stock split at ratio up to 1:30

## Summary
- Shareholders approved reverse stock split at ratio between 1:5 and 1:30, board to set exact ratio.
- Votes: 13,895,377 for, 1,341,351 against, 21,455 abstain; 62% quorum of outstanding shares.
- Reverse split must be executed by March 18, 2024, at board's discretion.
- Adjournment proposal also approved but not needed since main proposal passed.

## SEC filing metadata
- accession: 0001493152-23-041422
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315223041422/0001493152-23-041422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315223041422/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041422
- JSON: https://secwatch.observer/filing/0001493152-23-041422.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041422.txt

## Key facts
- Shareholder Votes
  Processa Pharmaceuticals, Inc. shareholders approved grant the Board of Directors discretionary authority to amend the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-5 and not more than 1-for-30 at the 2023-11-14 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-11-14
  source text: Non-Vote 13,895,377 1,341,351 21,455 - Proposal 2: Adjournment Proposal Shares For Against Abstain Broker
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315223041422/0001493152-23-041422-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.